Idarucizumab

依达赛珠单抗

Report date: 2026/03/23 20:03:44
First In Class

Base Information

Drug NameIdarucizumab
Drug Alias Name艾达赛珠单抗Idarucizumabum依达组单抗PraxbindPrizbind +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of Actionthrombin activators
TargetsProthrombin
Therapy Area/IndicationsHemorrhage
Global Approved IndicationsHemorrhage
Approved Indications in ChinaHemorrhage
Original Approved Country/TerritoryUnited States
Original Approved Date2015/10/16
Country/TerritoryCzechiaBelgiumCanada +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim International Gmbh
Inactive CompaniesBoehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim International Trading (Shanghai) Co Ltd
Active IndicationsHemorrhage
Inactive IndicationsN/A

Other Information

ATC CodeV03AB37
Related LinksWikipediaDrugBankKEGG